Legal status · Record reviewed
Retatrutide has no single legal status. It depends on the product and how it is supplied.
Still being studied in the United States; no FDA-approved retatrutide product. A research use only label does not make a product approved for people.
Sports: we have no current sports-rule review for it yet.
Rules for buying, selling, and prescribing also depend on how a product is made and sold, and on state law.
Whether you may buy, sell, or use a product also depends on pharmacy (compounding) rules, a prescription, and state law. Read how U.S. peptide law works.
Have a product in hand? Check if it is a prescription, compounded, or research-only product.
No FDA-approved product
The record found no FDA-approved product. A label that says research use only does not make a product approved for people.
What the record says: Still being studied in the United States; no FDA-approved retatrutide product
Not named on this FDA page
This FDA page does not name it. That does not show that a pharmacy may compound it. Other FDA lists and conditions still apply.
Source: FDA's page of bulk drug substances that may present significant safety risks. FDA marks it current as of . We checked it on .
Not assessed
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Check the current World Anti-Doping Agency list and your sport's rules before you compete.
Other names in this record: RETA, LY3437943, triple G agonist, triple hormone agonist.
What it is, what studies in people show, and what is still unknown.
Open the Retatrutide recordSee the FDA, compounding, and sports status of every peptide we reviewed in one table.
See all 34 peptides